Compare AstraZeneca plc (AZN) vs Schlumberger NV (SLB) Price & Performance

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

SLB trades at $53.20, up 5.28% over the past day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.55 versus $0.511 expected, driven by digital and production growth. Revenue for 2025 was $35.71 billion, with net income of $3.37 billion, though margins have compressed from prior years. The stock shows robust institutional support and positive media sentiment following upbeat results.

Outlook remains positive with a consensus price target of $63.00, implying 18% upside, supported by offshore and digital expansion. Risks include Middle East volatility and net debt concerns. The dividend yield is modest at around 1.1%, with the next payment scheduled for October 2026. Investors should weigh growth catalysts against regional and macroeconomic headwinds.